AusperBio adds $120M series C to advance hep B oligo therapy through phase 3 and beyond

AusperBio Therapeutics has raised $120 million in series C funds to advance its oligonucleotide therapy for chronic hepatitis B through phase 3 testing and hopefully on to commercialization.